Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Total stock-based compensation expense	$ 19,532	$ 15,009
Lucid Diagnostics Inc [Member]
Total stock-based compensation expense	14,991	9,599
Cost of Revenue [Member]
Total stock-based compensation expense	16
Selling and Marketing Expense [Member]
Total stock-based compensation expense	2,464	1,177
General and Administrative Expense [Member]
Total stock-based compensation expense	16,001	12,799
Research and Development Expense [Member]
Total stock-based compensation expense	1,051	1,033
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Cost of Revenue [Member]
Total stock-based compensation expense	13
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	968	8
Lucid Diagnostics Inc 2018 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	12,691	9,073
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	187	66
PAVmed Inc 2014 Equity Plan [Member] | Cost of Revenue [Member]
Total stock-based compensation expense	3
PAVmed Inc 2014 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	654	202
PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	262	38
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	$ 213	$ 212